Búsqueda | Portal de Búsqueda de la BVS España

1.

Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi^® and Epclusa^®.

Link, John O; Taylor, James G; Trejo-Martin, Alejandra; Kato, Darryl; Katana, Ashley A; Krygowski, Evan S; Yang, Zheng-Yu; Zipfel, Sheila; Cottell, Jeromy J; Bacon, Elizabeth M; Tran, Chinh V; Yang, Cheng Y; Wang, Yujin; Wang, Kelly W; Zhao, Guangyu; Cheng, Guofeng; Tian, Yang; Gong, Ruoyu; Lee, Yu-Jen; Yu, Mei; Gorman, Eric; Mogalian, Erik; Perry, Jason K.

Bioorg Med Chem Lett; 29(16): 2415-2427, 2019 08 15.

Artículo en Inglés | MEDLINE | ID: mdl-31230974

2.

Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi^®.

Taylor, James G; Zipfel, Sheila; Ramey, Kyla; Vivian, Randy; Schrier, Adam; Karki, Kapil K; Katana, Ashley; Kato, Darryl; Kobayashi, Tetsuya; Martinez, Ruben; Sangi, Michael; Siegel, Dustin; Tran, Chinh V; Yang, Zheng-Yu; Zablocki, Jeff; Yang, Cheng Y; Wang, Yujin; Wang, Kelly; Chan, Katie; Barauskas, Ona; Cheng, Guofeng; Jin, Debi; Schultz, Brian E; Appleby, Todd; Villaseñor, Armando G; Link, John O.

Bioorg Med Chem Lett; 29(16): 2428-2436, 2019 08 15.

Artículo en Inglés | MEDLINE | ID: mdl-31133531

3.

Identification of orally-bioavailable antagonists of the TRPV4 ion-channel.

Wei, Zhi-Liang; Nguyen, Margaret T; O'Mahony, Donogh J R; Acevedo, Alejandra; Zipfel, Sheila; Zhang, Qingling; Liu, Luna; Dourado, Michelle; Chi, Candace; Yip, Victor; DeFalco, Jeff; Gustafson, Amy; Emerling, Daniel E; Kelly, Michael G; Kincaid, John; Vincent, Fabien; Duncton, Matthew A J.

Bioorg Med Chem Lett; 25(18): 4011-5, 2015 Sep 15.

Artículo en Inglés | MEDLINE | ID: mdl-26235950

4.

Advances in cathepsin S inhibitor design.

Link, John O; Zipfel, Sheila.

Curr Opin Drug Discov Devel; 9(4): 471-82, 2006 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-16889230

5.

Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.

Goldstein, David M; Alfredson, Tom; Bertrand, Jay; Browner, Michelle F; Clifford, Ken; Dalrymple, Stacie A; Dunn, James; Freire-Moar, Jose; Harris, Seth; Labadie, Sharada S; La Fargue, JoAnn; Lapierre, Jean Marc; Larrabee, Susan; Li, Fujun; Papp, Eva; McWeeney, Daniel; Ramesha, Chakk; Roberts, Rick; Rotstein, David; San Pablo, Bong; Sjogren, Eric B; So, On-Yee; Talamas, Francisco X; Tao, Will; Trejo, Alejandra; Villasenor, Armando; Welch, Mary; Welch, Teresa; Weller, Paul; Whiteley, Phyllis E; Young, Kelly; Zipfel, Sheila.

J Med Chem; 49(5): 1562-75, 2006 Mar 09.

Artículo en Inglés | MEDLINE | ID: mdl-16509574

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi^® and Epclusa^®.

Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi^®.

Identification of orally-bioavailable antagonists of the TRPV4 ion-channel.

Advances in cathepsin S inhibitor design.

Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa®.

Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®.

Identification of orally-bioavailable antagonists of the TRPV4 ion-channel.

Advances in cathepsin S inhibitor design.

Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.

Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi^® and Epclusa^®.

Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi^®.